advertisement
Science News
from research organizations

Glaucoma: Seeing the light at the end of the (nano)tunnel

Date:
February 8, 2022
Source:
University of Montreal Hospital Research Centre (CRCHUM)
Summary:
A research team reveals the fine mechanisms behind the major vascular defects observed in glaucoma patients and identifies new therapeutic targets.
Share:
advertisement

FULL STORY

Reduced blood flow and impaired neurovascular coupling are well-known features of glaucoma, the main cause of non-curable blindness affecting 80 million people worldwide in 2020.

The mechanisms underlying these abnormalities are now unveiled, thanks to new research by a team led by Adriana Di Polo, professor of neuroscience and ophthalmology at Université de Montréal.

The study was published this week in theProceedings of the National Academy of Sciences.

The findings by Luis Alarcon-Martinez and Yukihiro Shiga, both postdoctoral fellows in Di Polo's laboratory and first co-authors of the study, reveal that nanotubes connecting pericytes are damaged in glaucoma leading to neurovascular deficits.

Pericytes are cells that have the ability to control the amount of blood passing through a single capillary simply by squeezing and releasing it. They are wrapped around the capillaries, the thinnest blood vessels in all organs of the body.

In living animals, as in humans, the retina uses the oxygen and nutrients contained in the blood to function properly. This vital exchange takes place through capillaries.

A blood story

"In our study, we used live imaging of the mouse retina and found significantly reduced capillary diameter and blood supply at pericyte locations in eyes with high intraocular pressure, the major risk factor to develop glaucoma," said Di Polo.

"We show that pericyte dysfunction impairs blood supply causing the death of retinal ganglion cells, the neurons that connect the retina with the brain, ultimately leading to vision loss."

"A key finding is that inter-pericyte tunnelling nanotubes, thin nanotubes used by pericytes to communicate with each other, were also damaged in hypertensive eyes and contributed to neurovascular dysfunction in glaucoma," added Alarcon-Martinez.

Calcium as a key player

Calcium entry into pericytes regulates their ability to constrict capillaries and control blood flow. In glaucoma, pericyte calcium influx is excessive, causing decreased blood supply.

"We showed that once the calcium equilibrium is restored within pericytes, vascular and neuronal functions can be recovered in glaucoma," said Shiga. "This strategy also prevented retinal ganglion cell death, therefore is an important preclinical proof of concept."

This study, the researchers say, paves the way for the development of therapeutic approaches that selectively target pericytes and calcium equilibrium to restore neurovascular health in glaucoma and potentially other neurodegenerative disorders with vascular components such as Alzheimer's disease.

advertisement

Story Source:

Materialsprovided byUniversity of Montreal Hospital Research Centre (CRCHUM).注意:内容可能被编辑风格d length.


Journal Reference:

  1. Luis Alarcon-Martinez, Yukihiro Shiga, Deborah Villafranca-Baughman, Nicolas Belforte, Heberto Quintero, Florence Dotigny, Jorge L. Cueva Vargas, Adriana Di Polo.Pericyte dysfunction and loss of interpericyte tunneling nanotubes promote neurovascular deficits in glaucoma.Proceedings of the National Academy of Sciences, 2022; 119 (7): e2110329119 DOI:10.1073/pnas.2110329119

Cite This Page:

University of Montreal Hospital Research Centre (CRCHUM). "Glaucoma: Seeing the light at the end of the (nano)tunnel." ScienceDaily. ScienceDaily, 8 February 2022. .
University of Montreal Hospital Research Centre (CRCHUM). (2022, February 8). Glaucoma: Seeing the light at the end of the (nano)tunnel.ScienceDaily. Retrieved July 7, 2023 from www.koonmotors.com/releases/2022/02/220207155718.htm
University of Montreal Hospital Research Centre (CRCHUM). "Glaucoma: Seeing the light at the end of the (nano)tunnel." ScienceDaily. www.koonmotors.com/releases/2022/02/220207155718.htm (accessed July 7, 2023).

Explore More
from ScienceDaily

RELATED STORIES